Abstract
Sickle cell disease (SCD) results in an inherited pattern of early morbidity and mortality for those affected, causing significant resource burdens on the healthcare system. Preimplantation genetic testing for monogenic diseases (PGT-M) uses next generation sequencing to identify unaffected embryos for transfer, allowing selection against genetically inherited disease processes. SCD, originating from a known single nucleotide point mutation, offers a precisely targeted opportunity for the use of PGT-M with highly sensitive and specific results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
